Get the Stockscreener App
0.7501
3.32%
0.0241
After Hours:
.75
-0.000100
-0.01%
Decoy Therapeutics Inc stock is traded at $0.7501, with a volume of 125.45K.
It is up +3.32% in the last 24 hours and down -7.96% over the past month.
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
See More
Previous Close:
$0.726
Open:
$0.7187
24h Volume:
125.45K
Relative Volume:
0.07
Market Cap:
$4.79M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+20.98%
1M Performance:
-7.96%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.69
$0.77
1-Week Range:
$0.63
$0.84
52-Week Range:
$0.615
$1.41
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Name
Decoy Therapeutics Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
0.7501 | 4.63M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Ladenburg Thalmann | Buy |
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Stock (DCOY) Latest News
Decoy Therapeutics Joins Webull Corporate Connect Service Platfo - GuruFocus
Decoy Therapeutics Joins Webull Corporate Connect Service Platform - marketscreener.com
Follow Decoy Therapeutics updates on Webull app now - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Finviz
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Gates Foundation backs Decoy's push for rapid, low-cost antivirals - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | DCOY Stock News - Longbridge
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Decoy Therapeutics (DCOY) Receives "Buy" Rating from Ladenburg T - GuruFocus
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
DCOY Stock Price, News & Analysis - Stock Titan
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics rises as Gates Foundation backs antiviral drug access - TradingView
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - The Globe and Mail
DCOY - Finviz
Salarius Pharmaceuticals changes name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Salarius Pharmaceuticals Changes Corporate Name to Decoy - GlobeNewswire
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - The Manila Times
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach - Investing.com UK
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewswire
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker - Investing.com
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - The Manila Times
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewswire
Salarius Pharmaceuticals clarifies continued Nasdaq listing after merger - Investing.com
Salarius Pharmaceuticals and Decoy Therapeutics Finalize Merger - citybiz
Salarius Pharmaceuticals Explorates Merger and Funding Moves - StocksToTrade
Salarius Pharmaceuticals, Inc. (SLRX) Stock: Plunges 51% After $7M Public Offering Announcement - parameter.io
Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger — Retail Bulls Bet On Breakout - Stocktwits
Salarius Pharmaceuticals amends merger terms, adjusts preferred stock conversion - Investing.com
Salarius Pharmaceuticals Regains Nasdaq Compliance with Minimum Bid Price Requirement - Quiver Quantitative
Salarius Pharmaceuticals appoints Mark J. Rosenblum as acting CEO - Investing.com
Salarius Pharmaceuticals Appoints New Acting CEO - TipRanks
Salarius Pharmaceuticals to implement 1-for-15 reverse stock split - Investing.com
Decoding Salarius Pharmaceuticals’ Stock Movement - timothysykes.com
Salarius Pharmaceuticals granted Nasdaq extension to regain listing compliance - Investing.com
Decoy Therapeutics Inc Stock (DCOY) Financials Data
There is no financial data for Decoy Therapeutics Inc (DCOY). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):